AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pujol, C.
Right arrow Articles by Soll, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pujol, C.
Right arrow Articles by Soll, D. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2004, p. 262-266, Vol. 48, No. 1
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.1.262-266.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Flucytosine Resistance Is Restricted to a Single Genetic Clade of Candida albicans

Claude Pujol,1 Michael A. Pfaller,2 and David R. Soll1*

Department of Biological Sciences,1 Department of Pathology, The University of Iowa, Iowa City, Iowa 522422

Received 11 August 2003/ Returned for modification 22 September 2003/ Accepted 30 September 2003

Population studies have revealed that Candida albicans can be separated into five major clades, groups I, II, III, SA, and E. Groups SA and E are highly prevalent in South Africa and Europe, respectively, while group II is excluded from the southwestern portion of the United State. In each geographical locale, several clades exist side by side, suggesting little interclade recombination. These results suggest clade-specific phenotypes. In the present study we demonstrate that resistance to flucytosine (5FC MIC >= 32 µg/ml), an antifungal used for the treatment of systemic C. albicans infections, is restricted to clade I. In addition, while 97% of all strains for which 5FC MICs were >=0.5 µg per ml were members of group I, only 3% were members of the other groups. 5FC MICs were >=0.5 µg per ml for 72% of all group I isolates, while 5FC MICs were >=0.5 µg per ml for only 2% of all non-group I isolates. These results demonstrate for the first time the clade specificity of a clinically relevant trait (5FC resistance) and suggest that while intraclade recombination may be common, interclade recombination is rare.


* Corresponding author. Mailing address: Department of Biological Sciences, 302 BBE, The University of Iowa, Iowa City, IA 52242. Phone: (319) 335-1117. Fax: (319) 335-2772. E-mail: david-soll{at}uiowa.edu.


Antimicrobial Agents and Chemotherapy, January 2004, p. 262-266, Vol. 48, No. 1
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.1.262-266.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2004 by the American Society for Microbiology. All rights reserved.